ARAV Aravive, Inc. Stock Quote

ARAV [NASD]

Index	-	P/E	-	EPS (ttm)	-2.05	Insider Own	1.20%	Shs Outstand	16.06M	Perf Week	1.58%
Market Cap	90.94M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	9.29%	Shs Float	11.23M	Perf Month	-7.79%
Income	-30.80M	PEG	-	EPS next Q	-0.52	Inst Own	41.00%	Short Float	5.81%	Perf Quarter	11.54%
Sales	0.00M	P/S	-	EPS this Y	85.20%	Inst Trans	-0.14%	Short Ratio	4.31	Perf Half Y	-35.56%
Book/sh	3.07	P/B	1.89	EPS next Y	7.20%	ROA	-43.10%	Target Price	-	Perf Year	-46.84%
Cash/sh	3.44	P/C	1.68	EPS next 5Y	-	ROE	-52.10%	52W Range	3.34 - 14.94	Perf YTD	2.84%
Dividend	-	P/FCF	-	EPS past 5Y	43.10%	ROI	-	52W High	-61.18%	Beta	3.24
Dividend %	-	Quick Ratio	11.40	Sales past 5Y	-	Gross Margin	-	52W Low	73.65%	ATR	0.38
Employees	17	Current Ratio	11.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.48	Volatility	6.13% 6.21%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-22.00%	Profit Margin	-	Rel Volume	0.66	Prev Close	5.64
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	Payout	-	Avg Volume	151.21K	Price	5.80
Recom	1.70	SMA20	0.55%	SMA50	-0.33%	SMA200	-27.69%	Volume	100,043	Change	2.84%

Sep-18-20

Initiated

William Blair

Outperform

Dec-10-19

Initiated

Cantor Fitzgerald

Overweight

Dec-02-19

Upgrade

Robert W. Baird

Neutral → Outperform

May-13-19

Initiated

Piper Jaffray

Overweight

$10

Apr-09-19

Initiated

Wedbush

Outperform

$14

Jan-04-21 04:05PM	Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference GlobeNewswire -5.14%
Dec-31-20 07:00PM	Aravive Announces Board Member Transition to Advisory Role GlobeNewswire -5.69%
Dec-07-20 09:37PM	Is ARAV A Good Stock To Buy Now? Insider Monkey
Nov-19-20 07:00AM	Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer GlobeNewswire
Nov-16-20 11:19PM	Here's Why We're Not Too Worried About Aravive's (NASDAQ:ARAV) Cash Burn Situation Simply Wall St. +13.00%
04:05PM	Aravive to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-10-20 04:05PM	Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020 GlobeNewswire +9.00%
07:00AM	Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China GlobeNewswire
Nov-05-20 04:05PM	Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates GlobeNewswire
Sep-17-20 07:00AM	Aravive Appoints Michael W. Rogers to Board of Directors GlobeNewswire
Sep-15-20 07:00AM	Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer GlobeNewswire +6.39%
Sep-08-20 07:00AM	Aravive to Participate in Upcoming Virtual Investor Conferences in September GlobeNewswire
Aug-27-20 07:00AM	Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans GlobeNewswire
Aug-13-20 03:30PM	Wedbush: 3 Healthcare Stocks Under $10 With Massive Upside Ahead TipRanks
Aug-03-20 04:01PM	Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates GlobeNewswire
Jul-30-20 07:00AM	Aravive to Participate in Upcoming Virtual Investor Conferences in August GlobeNewswire
Jul-23-20 07:00AM	Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer GlobeNewswire -13.38%
Jul-03-20 01:11PM	What Kind Of Investors Own Most Of Aravive, Inc. (NASDAQ:ARAV)? Simply Wall St.
Jul-01-20 08:12AM	The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes Benzinga
Jun-30-20 04:05PM	Aravive Added to the Russell 2000® and Russell 3000® Indexes GlobeNewswire
Jun-24-20 05:45PM	Aravive (ARAV) Stock Moves -1.47%: What You Should Know Zacks
Jun-17-20 05:50PM	Aravive (ARAV) Dips More Than Broader Markets: What You Should Know Zacks
Jun-12-20 12:04PM	Hedge Funds Are Dumping Aravive, Inc. (ARAV) Insider Monkey
May-12-20 08:00AM	Aravive To Present at The 2020 RBC Capital Markets Global Healthcare Conference GlobeNewswire -5.80%
May-06-20 04:05PM	Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates GlobeNewswire
12:30PM	Aravive (ARAV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
May-05-20 05:45PM	Aravive (ARAV) Flat As Market Gains: What You Should Know Zacks
Apr-30-20 08:00AM	Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody Platform GlobeNewswire +6.25%
Apr-27-20 05:45PM	Aravive (ARAV) Gains But Lags Market: What You Should Know Zacks
11:30AM	Is ARAVIVE, INC (ARAV) Outperforming Other Medical Stocks This Year? Zacks
Apr-22-20 07:10AM	Aravive's Shares March Higher, Can It Continue? Zacks
Apr-20-20 09:06AM	Top Ranked Momentum Stocks to Buy for April 20th Zacks +5.96%
08:51AM	bluebird bio (BLUE) Catches Eye: Stock Jumps 6% Zacks
Apr-16-20 10:40AM	Aravive (ARAV) in Focus: Stock Moves 8% Higher Zacks
09:16AM	Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6% Zacks
Apr-15-20 08:45AM	Aravive (ARAV): Strong Industry, Solid Earnings Estimate Revisions Zacks +8.04%
Apr-09-20 07:08AM	Aravive Announces Board Composition and Executive Management Transitions GlobeNewswire +20.94%
Mar-30-20 08:00AM	Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer GlobeNewswire
06:17AM	We're Not Very Worried About Aravive's (NASDAQ:ARAV) Cash Burn Rate Simply Wall St.
Mar-27-20 08:00AM	Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates GlobeNewswire +9.53%
Mar-24-20 08:00AM	Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN) GlobeNewswire +12.16%
Feb-25-20 04:07PM	Aravive To Present at The Cowen and Company 40th Annual Health Care Conference GlobeNewswire
Feb-18-20 08:00AM	Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial GlobeNewswire
Jan-13-20 08:00AM	Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma GlobeNewswire
Jan-10-20 07:13AM	The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga
Jan-09-20 04:05PM	Aravive Announces Management Changes GlobeNewswire
Jan-02-20 08:34AM	3 Healthcare Stocks Primed for 2020 Gains TipRanks
Dec-23-19 07:57PM	Is Aravive, Inc. (ARAV) A Good Stock To Buy? Insider Monkey
Dec-20-19 08:00AM	Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis GlobeNewswire
Dec-02-19 08:00AM	Aravive Announces Participation at the 2019 Piper Jaffray Healthcare Conference GlobeNewswire +10.71%
Nov-29-19 08:51AM	Implied Volatility Surging for Aravive (ARAV) Stock Options Zacks +16.61%
Nov-27-19 08:30AM	Aravive Announces Pricing of Public Offering of Common Stock GlobeNewswire -12.23%
07:26AM	The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen Benzinga
Nov-26-19 05:14PM	Aravive Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-20-19 04:26PM	Here's Why This Tiny Biotech Stock Briefly Doubled In Value Overnight Investor's Business Daily +44.10%
08:35AM	Aravive shares jump on ovarian cancer data MarketWatch
07:00AM	Aravive Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer GlobeNewswire
Nov-12-19 08:00AM	Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer GlobeNewswire
Nov-08-19 01:11PM	CORRECTION Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates GlobeNewswire
Nov-07-19 04:05PM	Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates GlobeNewswire
Nov-03-19 07:41AM	Does Aravive, Inc.'s (NASDAQ:ARAV) CEO Salary Compare Well With Others? Simply Wall St.
Oct-18-19 08:00AM	Aravive Announces Publication of AVB-500 Nonclinical Study in Treatment-Resistant ccRCC Animal Models in Cancer Research GlobeNewswire
Sep-27-19 10:15AM	Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona GlobeNewswire
08:00AM	Aravive Announces Participation at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-19-19 08:13AM	Will Aravive, Inc. (NASDAQ:ARAV) Need To Raise More Money? Simply Wall St. +16.43%
Sep-18-19 08:00AM	Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona GlobeNewswire +17.23%
Aug-08-19 04:15PM	Aravive Announces Executive Management Transition Plan GlobeNewswire
08:00AM	Aravive Announces Participation at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-07-19 08:55PM	Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Aravive Reports Second Quarter 2019 Financial Results and Provides Recent Corporate Updates GlobeNewswire
Jul-31-19 03:16PM	Introducing Aravive (NASDAQ:ARAV), The Stock That Collapsed 95% Simply Wall St. +12.37%
07:05AM	Aravive Reports Preliminary Results of AVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial GlobeNewswire
Jul-08-19 07:05AM	Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients GlobeNewswire
May-08-19 06:35PM	Aravive: 1Q Earnings Snapshot Associated Press
04:05PM	Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates GlobeNewswire
Apr-25-19 02:26PM	Do Insiders Own Shares In Aravive, Inc. (NASDAQ:ARAV)? Simply Wall St. -10.32%
Mar-19-19 07:05AM	Aravive Announces Retrospective Analysis Showing Increased GAS6 Levels Associated with Chemoresistance and Decreased Progression Free Survival in Ovarian Cancer GlobeNewswire +16.52%
Mar-15-19 07:48AM	Aravive Inc (ARAV) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-11-19 02:14PM	Heres What We Think About Aravive, Inc.s (NASDAQ:ARAV) CEO Pay Simply Wall St.
Mar-08-19 04:05PM	CORRECTING AND REPLACING - Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Mar-07-19 04:04PM	Aravive Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Corporate Updates GlobeNewswire
Mar-05-19 04:05PM	Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference GlobeNewswire +5.41%
Feb-28-19 04:10PM	Aravive to Report Fourth Quarter and Full Year 2018 Financial Results and Corporate Updates on March 7, 2019 GlobeNewswire +8.16%
Feb-19-19 07:00AM	Aravive Receives Additional $2.6 Million Disbursement from the Cancer Prevention and Research Institute of Texas GlobeNewswire +10.29%
Feb-14-19 07:00AM	Aravive Expands Executive Team with Promotion of Gail McIntyre, PhD, DABT to Chief Scientific Officer GlobeNewswire
Jan-29-19 07:00AM	Aravive to Host Key Opinion Leader Breakfast Symposium on AVB-S6-500 and the GAS6-AXL Pathway on February 5, 2019 GlobeNewswire
Dec-11-18 08:05AM	Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer GlobeNewswire
Nov-26-18 07:00AM	Aravive Announces Participation at Upcoming Investor Conference GlobeNewswire
Nov-13-18 07:00AM	Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium GlobeNewswire
Nov-06-18 06:38PM	Versartis: 3Q Earnings Snapshot Associated Press +7.71%
04:05PM	Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates GlobeNewswire

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shah Vinay	Chief Financial Officer	Dec 04	Buy	5.76	8,000	46,080	189,842	Dec 07 08:05 PM
McIntyre Gail Frances	CEO and President	Dec 04	Buy	5.77	8,000	46,160	10,137	Dec 07 08:00 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience